The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of clofarabine and liposomal daunorubicin in childhood acute myeloid leukemia.
P. Kearns
Consultant or Advisory Role - Genzyme (U)
N. J. Graham
No relevant relationships to disclose
M. Cummins
No relevant relationships to disclose
B. Gibson
Consultant or Advisory Role - Genzyme (U)
J. D. Grainger
No relevant relationships to disclose
R. Keenan
No relevant relationships to disclose
D. Lancaster
No relevant relationships to disclose
G. Shenton
No relevant relationships to disclose
J. Vormoor
No relevant relationships to disclose
D. Webb
No relevant relationships to disclose
I. Hawley
No relevant relationships to disclose
P. J. Johnson
No relevant relationships to disclose